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Background and purpose: The purpose was to examine the consequences of
antiepileptic drug (AED) exposure during pregnancy on language abilities in
children aged 5 and 8 years of mothers with epilepsy.
Methods: The study population included children of mothers with and with-
out epilepsy enrolled in the Norwegian Mother and Child Cohort Study 1999–
2008. Mothers prospectively provided information on epilepsy diagnosis, AED
use during pregnancy and the child’s language abilities at age 5 and 8 years,
in questionnaires with validated language screening tools. AED concentrations
in gestation week 17–19 and in the umbilical cord were measured.
Results: The study population included 346 AED-exposed and 388 AED-un-
exposed children of mothers with epilepsy, and 113 674 children of mothers
without epilepsy. Mothers of 117 and 121 AED-exposed children responded to
the questionnaires at age 5 and 8 years, respectively. For AED-exposed chil-
dren, the adjusted odds ratio for language impairment was 1.6 [confidence
interval (CI) 1.1–2.5, P = 0.03] at age 5 years and 2.0 (CI 1.4–3.0, P < 0.001)
at age 8 years, compared to children of mothers without epilepsy. Children
exposed to carbamazepine monotherapy had a significantly increased risk of
language impairment compared to control children at age 8 years (adjusted
odds ratio 3.8, CI 1.6–9.0, P = 0.002). Higher maternal valproate concentra-
tions correlated with language impairment at age 5 years. Periconceptional
folic acid supplement use protected against AED-associated language impair-
ment.
Conclusion: Foetal AED exposure in utero is associated with an increased risk
of language impairment in children aged 5 and 8 years of mothers with epi-
lepsy. Periconceptional folic acid use had a protective effect on AED-associ-
ated language impairment.
Introduction
Foetal antiepileptic drug (AED) exposure in utero is
associated with adverse neurodevelopmental effects in
infancy and early childhood in children of mothers
with epilepsy, particularly after valproate exposure
[1–3]. Such effects include low intelligence quotient
(IQ), poor language abilities and an increased risk of
behavioural disorders such as autism spectrum disor-
der and attention deficit and hyperactivity disorder
[1,2]. Evidence on the long-term effects of foetal AED
exposure on language abilities is emerging, but data
are limited, particularly for newer AEDs such as lam-
otrigine, levetiracetam and topiramate [1,3]. After
AED exposure in utero, verbal abilities and verbal IQ
can be reduced in children aged 5–9 years, particularly
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for valproate [4–8] and this reduction might be perma-
nent [9]. Data regarding carbamazepine exposure and
language performance are conflicting [1,2]. Few stud-
ies have examined the influence of AED concentra-
tions during pregnancy on language abilities in older
children. It has been shown previously that language
impairment and risk of autistic traits at age 1.5 and
3 years depend on maternal plasma AED concentra-
tions and folate status [10–12].
This study presents data from the epilepsy popula-
tion in the Norwegian Mother and Child Cohort
Study (MoBa) after 8 years of follow-up. The aim of
the study was to examine the effect of foetal AED
exposure and plasma AED concentrations during
pregnancy on language abilities in children at age 5
and 8 years of mothers with epilepsy.
Material and methods
Study population
The study population consisted of children of mothers
with and without epilepsy included in the MoBa. This
is an ongoing, prospective, population-based pregnancy
cohort study conducted by the Norwegian Institute of
Public Health and linked to the compulsory Medical
Birth Registry of Norway (MBRN) [13]. The overall
participation rate was 41%. The mothers answered
questionnaires during week 17–19 (Q1) and week 30
(Q2) in the pregnancy, and after the child was born at
age 6 months (Q3), 1.5 years (Q4), 3 years (Q5),
5 years (Q5Y) and 8 years (Q8Y) (Fig. 1). The ques-
tionnaires obtained information regarding maternal
medical and social background, medication and vita-
min use and maternal health during the pregnancy, and
detailed information regarding child development,
including language abilities. Blood samples were col-
lected from the mothers in gestation week 17–19 and
from the umbilical cord immediately after birth [13,14].
Our data were based on version X of the MoBa data-
bank and included 734 children of 620 mothers with epi-
lepsy and 113 674 children of 94 338 mothers without
epilepsy. The epilepsy diagnosis [15] was based on self-
reported information from the MoBa questionnaires as
well as information from the MBRN registered by the
family doctor or midwife. The epilepsy cohort in MoBa
has been validated previously (Appendix S1: Methods
S1), and the validity is very good [16].
Variables
Antiepileptic drug use and plasma AED concentrations
Information on type of AED use during the pregnancy
was obtained from Q1 and Q2, and from MBRN data
[13]. Plasma concentrations of valproate, lamotrigine,
carbamazepine, oxcarbazepine monohydroxyderivative
metabolite, levetiracetam and topiramate were analysed
in 226 maternal blood samples (gestational week 17–19)
and 198 umbilical cord samples for altogether 254 AED-
exposed children (73%) [14,16]. The reported AED was
detected in samples from 237 of the 254 children (93%)
(Appendix S1: Methods S1).
Maternal folate status
Mothers in the MoBa reported on the use and frequency
of intake of folic acid supplement during pregnancy in
Q1 and Q2 (Appendix S1: Methods S1). Periconcep-
tional folic acid supplement use was defined as use 4
weeks before pregnancy and/or during the first trimester.
There are no compulsory folic acid food fortifications in
Norway. Plasma folate concentrations were analysed in
maternal blood samples from gestation week 17–19
(Appendix S1: Methods S1) [14].
Language impairment
The definition of language impairment was based on the
following parent-reported screening instruments in the
MoBa: the communication scale from the Ages and
Stages Questionnaires (ASQ) [17,18] the Speech and
Language Assessment Scale (SLAS) [19] and the Norwe-
gian instrument Twenty Statements about Language-re-
lated Difficulties (Language 20) (Appendix S1: Methods
S1 and Table S1) [20]. All three instruments were avail-
able in Q5Y, only the latter being available in Q8Y. Chil-
dren at age 5 years with results outside the cut-off for at
least one of the three parent-reported instruments in
Q5Y were defined to have language impairment. Simi-
larly, children at age 8 years with a result above cut-off
for the Language 20 semantic subscale in Q8Y were clas-
sified with language impairment. Criteria for language
impairment at age 1.5 and 3 years have been described
elsewhere [12]. Children who fill criteria for language
impairment by any of the screening instruments are rec-
ommended for referral for clinical assessment and diag-
nosis [18–20]
Covariates
Covariates from the MoBa questionnaires and MBRN
based on clinical relevance were included [12,21]
(Table 1, Appendix S1: Methods S1 and Fig. S1).
Statistical analysis
Missing data analyses were performed by comparing
the clinical characteristics of children who responded
and did not respond to Q5Y and Q8Y (Appendix S1:
Methods S1, Tables S2 and S3). AED-exposed and
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AED-unexposed children of mothers with epilepsy
were compared with the control group of all children
of mothers without epilepsy (Appendix S1: Methods
S1).
Ethics
This study was approved by the Regional Committee
for Medical Research Ethics (reference number 2011/
1616) (Appendix S1: Methods S1).
Results
Sample characteristics
The study population consisted of 346 AED-exposed
and 388 AED-unexposed children of mothers with
epilepsy, and a control group of 113 674 children of
mothers without epilepsy (Table 1 and Fig. 1). Of the
AED-exposed children, 280 children were exposed to
AED monotherapy and 64 to AED polytherapy
(Appendix S1: Table S4). For two children, the AED
regime was unspecified. The most frequent AED expo-
sures in monotherapy were lamotrigine (n = 112), car-
bamazepine (n = 72) and valproate (n = 40). Of the
early pregnancy folic acid users, 97% of the total
study population used it four times per week or more
(Q1), and the same was true for 91% of the late users
(Q2). Mothers of 117 and 121 of the AED-exposed
children responded to Q5Y and Q8Y (Fig. 1). For
AED-exposed children, no periconceptional folic acid
supplementation, smoking during pregnancy, male off-
spring and previous language impairment at an earlier
age were predictors of language impairment at age 5
or 8 years (Table 2). Of the AED-exposed children
with language impairment at age 1.5 or 3 years, 41%
(n = 22) continued to have such at age 5 or 8 years
(Appendix S1: Fig. S2).
Antiepileptic drug use and language impairment
At age 5 years, 30% (n = 35) of AED-exposed children
had language impairment compared to 22% (n = 9011)
amongst children of mothers without epilepsy
(P = 0.04). The adjusted odds ratio (aOR) for language
impairment was 1.6 [confidence interval (CI) 1.1–2.5,
P = 0.03) (Table 3). At age 8 years, 32% (n = 38) of
AED-exposed children had language impairment com-
pared to 19% (n = 8250) in the control group
(P < 0.001); the aOR was 2.0 (CI 1.4–3.0, P < 0.001)
(Table 3). There were no significant differences in lan-
guage impairment between AED-unexposed children of
mothers with epilepsy and the control group.
Children exposed to carbamazepine monotherapy
had significantly higher risk of language impairment
compared to control children at age 8 years (aOR 3.8,
Figure 1 Flow chart of included and excluded cases. AED yes, AED-exposed children, AED no, AED-unexposed children.
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CI 1.6–9.0, P = 0.002, n = 23) but not at age 5 years
(aOR 1.9, CI 0.6–5.6, P = 0.26, n = 17) (Table 3).
Children exposed to valproate monotherapy in utero
had the poorest mean language scores at both ages
(Table 4).
Antiepileptic drug concentrations and language
impairment
Higher maternal plasma valproate concentration dur-
ing pregnancy correlated with a lower ASQ score
(Spearman’s rho 0.77, P = 0.02, n = 9) and a higher
Language 20 score (Spearman’s rho 0.82, P = 0.01,
n = 9), both indicating language impairment at age
5 years (Fig. 2 and Appendix S1: Table S5). A signifi-
cant correlation between higher maternal carba-
mazepine concentration and lower Language 20 score
(Spearman’s rho 0.47, P = 0.04, n = 19), indicating
less language impairment, appeared at age 5 years,
but the scatter plot contained outliers influencing the
association (Appendix S1: Table S5).
Maternal folate status and language impairment
In the mothers not taking folic acid supplementation,
63% (n = 5) of AED-exposed children had language












n = 113 674
Male offspring; n (%) 168 (49) 195 (51) 57 958 (51)
Gestational age at birtha (weeks); median (range) 40.0 (27.0) 39.0 (18.0) 40.0 (32.0)
Apgar score 5 min after birth; median (range) 10 (10.0) 10 (10.0) 10 (10.0)
Twin or triplet child; n (%) 10 (3) 20 (5) 3918 (4)
Parityb; median (range) 1.0 (4.0) 1.0 (4.0) 1.0 (4.0)
Maternal age (years); median (range) 29.0 (24.0) 29.0 (25.0) 30.0 (39.0)
Maternal prepregnancy BMI (kg/m2); median (range) 23.6 (26.4) 23.6 (25.9) 23.1 (47.0)
Periconceptional folic acid usec 259 (79) 289 (75) 77 895 (76)
Single mother; n (%) 15 (5) 17 (4) 2418 (2)
Paternal low educationd; n (%) 20 (6) 23 (6) 4692 (4)
Maternal low educationd; n (%) 12 (4) 21 (5) 2825 (3)
Low total household incomee; n (%) 35 (11) 35 (10) 6464 (7)
Unplanned pregnancy; n (%) 76 (24) 90 (24) 19 725 (19)
Alcohol during pregnancyf; n (%) 12 (4) 9 (2) 2670 (3)
Smoking during pregnancy; n (%) 40 (12) 32 (8) 9525 (9)
Maternal anxiety/depression during pregnancyg; n (%) 62 (20) 56 (15) 10 821 (11)
≥1 epileptic seizure during pregnancy; n (%) 42 (26) 13 (7) NA
TC seizure(s) during pregnancy; n (%) 20 (12) 5 (3) NA
Maternal report of familial language
impairmenth at age 5 years
47 (41) 63 (42) 14 163 (35)
Maternal report of seldom/never
helping their child read letters and
sounds during a typical week at age 5 years
17 (15) 22 (15) 6675 (16)
Maternal report of never reading to
their child at age 8 years
6 (5) 9 (6) 2959 (7)
Language impairment age 1.5 yearsi 43 (20) 24 (9) 7896 (11)
Language impairment age 3 yearsj 22 (12) 14 (7) 4182 (7)
AED, antiepileptic drug; BMI, body mass index; TC seizure(s), tonic–clonic seizure(s). N may vary within the groups due to missing data. The
chi-squared test for independence or Fisher’s exact test was used for categorical variables, the Mann–Whitney U test for continuous variables
due to violation of the assumption of normal distribution. AED-exposed and AED-unexposed children are compared to children of mothers
without epilepsy. aCalculated from the ultrasonographic measurements performed at 18–19 weeks of gestation. When ultrasound data were
unavailable, gestational age was estimated on the basis of the first day of the last menstrual period. bNumber of all pregnancies >21 gestation
weeks including the current pregnancy. Maximum value is 5, representing a parity of 5 or more. cMaternal folic acid supplement use 4 weeks
before pregnancy and/or during the first trimester. d9 or fewer years of schooling. e < 400 000 NOK (equals approximately 41 000 EUR) annu-
ally. fAlcohol consumption ≥1 time per month. gMean score >1.75 on the Hopkins symptom check list in gestational week 17–19. hMaternal
report of a biological relative (sibling, parent, grandparent, aunt, uncle or cousin) who was a late talker or had difficulties with either reading
or writing or pronunciation. iDefined as children who score 1.5 standard deviations or more below the mean score of the three-item version of
the communication scale from the Ages and Stages Questionnaires at age 1.5 years. jDefined as children who score 1.5 standard deviations or
more below the mean score of the six-item version of the communication scale from the Ages and Stages Questionnaires at age 3 years and/or
are talking in two- to three-word phrases or fewer (expressive language impairment) at age 3 years.
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impairment at age 5 years compared to 23%
(n = 1422) of children of mothers without epilepsy
(P = 0.02) (Appendix S1: Table S6). Similarly, at age
8 years, 52% (n = 11) of AED-exposed children had
language impairment compared to 22% (n = 1712) in
the non-supplemented control group (P = 0.002)
(Appendix S1: Table S6). The aORs for language
impairment in AED-exposed children compared to
control children with no folic acid use were 10.5 (CI
1.9–56.3, P = 0.006) at age 5 years and 3.8 (CI 1.6–
9.1, P = 0.003) at age 8 years, respectively. When the
mothers were using periconceptional folic acid
Table 2 Clinical characteristics of AED-exposed and AED-unexposed children of mothers with epilepsy and children of mothers without epi-








Children of mothers without






(33%) OR (95% CI)
Yesn = 14 392
(26%) OR (95% CI)
Male offspring; n (%b) 39 (47) 3.1 (1.6–6.1)* 34 (33) 1.0 (0.6–1.9) 8503 (30) 1.6 (1.5–1.6)*
Gestational age at birthc (weeks); median
(range)
40.0 (17.0) 1.0 (0.9–1.2) 39.0 (14.0) 0.9 (0.8–1.0) 40.0 (22.0) 1.0 (1.0–1.0)*
Apgar score 5 min after birth; median (range) 9.0 (5.0) 1.0 (0.7–1.4) 9.0 (10.0) 0.9 (0.7–1.1) 10.0 (10.0) 0.9 (0.9–1.0)*
Twin or triplet child; n (%) 2 (33) 0.9 (0.2–5.3) 3 (38) 1.2 (0.3–5.3) 485 (31) 1.3 (1.1–1.4)*
Parityd; median (range) 2.0 (4.0) 1.3 (0.9–1.8) 1.0 (3.0) 1.0 (0.7–1.5) 2.0 (4.0) 1.0 (0.9–1.0)*
Maternal age (years); median (range) 31.0 (21.0) 1.0 (0.9–1.1) 29.0 (20.0) 1.0 (0.9–1.0) 30.0 (32.0) 1.0 (1.0–1.0)*
Maternal prepregnancy BMI (kg/m2); median
(range)
23.2 (23.7) 1.0 (0.9–1.1) 22.8 (24.0) 1.0 (0.9–1.1) 23.2 (38.2) 1.0 (1.0–1.0)*
Periconceptional folic acid usee 42 (31) 0.4 (0.2–0.9)* 54 (34) 1.2 (0.6–2.6) 11,538 (26) 1.0 (0.9–1.0)
Single mother; n (%) 2 (50) 1.9 (0.3–14.2) 1 (33) 1.0 (0.1–11.3) 298 (31) 1.3 (1.1–1.5)*
Maternal low educationf; n (%) 0 (0) NA 4 (80) 8.7 (1.0–79.5) 323 (41) 2.0 (1.7–2.3)*
Low total household incomeg; n (%) 5 (50) 2.2 (0.6–8.0) 5 (46) 1.8 (0.5–6.0) 851 (32) 1.4 (1.3–1.5)*
Unplanned pregnancy; n (%) 12 (36) 1.1 (0.5–2.5) 11 (37) 1.2 (0.5–2.8) 2599 (28) 1.1 (1.1–1.2)*
Alcohol during pregnancyh; n (%) 1 (50) 1.9 (0.1–31.4) 2 (67) 4.2 (0.4–47.4) 358 (27) 1.0 (0.9–1.2)
Smoking during pregnancy; n (%) 8 (62) 3.3 (1.0–10.7)* 4 (40) 1.4 (0.4–5.1) 856 (31) 1.3 (1.2–1.4)*
Maternal anxiety/depression during
pregnancyi; n (%)
8 (36) 1.1 (0.4–2.7) 10 (40) 1.5 (0.6–3.5) 1737 (35) 1.6 (1.5–1.7)*
≥1 epileptic seizure during pregnancy; n (%) 13 (41) 1.4 (0.6–3.2) 7 (70) 5.8 (1.4–23.9)* NA NA
TC seizure(s) during pregnancy; n (%) 6 (35) 1.0 (0.3–3.0) 4 (100) NA NA NA
AED polytherapy during pregnancy; n (%) 11 (33) 0.9 (0.4–2.1) NA NA NA NA
AED monotherapy during pregnancy; n (%) 45 (35) 1.0 (0.5–2.3) NA NA NA NA
Plasma AED (µmol/l)j; median (range) 53.2 (170) 1.0 (1.0–1.0) NA NA NA NA
Maternal report of familial language
impairmentk at age 5 years
17 (36) 1.4 (0.6–3.0) 24 (38) 1.4 (0.7–2.8) 4844 (34) 1.6 (1.6–1.7)
Maternal report of seldom/never reading to
their childl
9 (39) 1.2 (0.5–3.1) 12 (43) 1.7 (0.7–3.7) 3354 (37) 1.8 (1.8–1.9)*
Language impairment age 1.5 yearsm 17 (59) 3.9 (1.7–9.2)* 12 (67) 4.8 (1.7–13.6)* 2608 (51) 3.4 (3.2–3.6)*
Language impairment age 3 yearsn 14 (82) 12.0 (3.2–44.4)* 3 (33) 1.0 (0.2–4.0) 2080 (71) 7.9 (7.3–8.6)*
AED, antiepileptic drug; BMI, body mass index; CI, confidence interval; OR, odds ratio; TC seizure(s), tonic–clonic seizure(s). N may vary
slightly within the groups due to missing data. Significant results are marked with bold values. aLanguage impairment at age 5 years according
to the Ages and Stages Questionnaires, the Speech and Language Assessment Scale or the Twenty Statements about Language-related Difficul-
ties or at age 8 years according to the Twenty Statements about Language-related Difficulties semantic subscale. bPercentage was calculated
from the number of children with that characteristic and language impairment out of all children with that characteristic in each of the three
groups. cCalculated from the ultrasonographic measurements performed at 18–19 weeks of gestation. When ultrasound data were unavailable,
gestational age was estimated on the basis of the first day of the last menstrual period. dNumber of all pregnancies >21 gestation weeks includ-
ing the current pregnancy. Maximum value is 5, representing a parity of 5 or more. eFolic acid supplement use 4 weeks before pregnancy and/
or during the first trimester. f9 or fewer years of schooling. g<400 000 NOK (equals approximately 41 000 EUR) annually. hAlcohol consump-
tion ≥1 time per month. iMean score >1.75 on the Hopkins symptom check list in gestational week 17–19. jMedian of standardized concentra-
tion (see text) in maternal plasma at gestational week 17–19 and umbilical cord blood. kMaternal report of a biological relative (sibling,
parent, grandparent, aunt, uncle or cousin) who was a late talker or had difficulties with either reading or writing or pronunciation. lMaternal
report of seldom/never helping their child read letters and sounds during a typical week at age 5 years or maternal report of never reading to
their child age 8 years. mDefined as children who score 1.5 standard deviations or more below the mean score of the three-item version of the
communication scale from the Ages and Stages Questionnaires at age 1.5 years. nDefined as children who score 1.5 standard deviations or
more below the mean score of the six-item version of the communication scale from the Ages and Stages Questionnaires at age 3 years and/or
are talking in two- to three-word phrases or fewer (expressive language impairment) at age 3 years. *P value <0.05.
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supplement, the corresponding aORs for language
impairment were 1.4 (CI 0.9–2.2, P = 0.14) at age
5 years and 1.7 (CI 1.1–2.6, P = 0.02) at age 8 years,
respectively.
After adjustment for covariates, a significant inter-
action was found between periconceptional folic acid
use and AED exposure for ASQ score at age 5 years
(P = 0.009, standardized beta 0.03), but not for SLAS
or Language 20 scores at age 5 or 8 years. In the lin-
ear regression model, maternal folate concentration
correlated with Language 20 score at age 5 years in
the unadjusted, but not in the adjusted, model.
Discussion
An increased risk of language impairment was found
in AED-exposed children at age 5 and 8 years of
mothers with epilepsy compared to children of moth-
ers without epilepsy. Valproate and carbamazepine
exposure affected language outcome the most. Peri-
conceptional folic acid use had a protective effect on
the risk of language impairment. There was no
increased risk of language impairment in AED-unex-
posed children of mothers with epilepsy compared to
children of mothers without epilepsy. A large number
of other possible confounders was considered, and
these did not have any consistent effect on language
outcome. AED exposure, and especially if the mother
did not take folic acid, was the single most important
factor for language outcome.
The AED-associated risk of language impairment
was particularly evident in the carbamazepine
monotherapy group at age 8 years. The aOR for lan-
guage impairment in this group was almost fourfold
compared to children of mothers without epilepsy.
Poor neurodevelopmental outcomes after AED expo-
sure in utero have mostly been associated with val-
proate exposure [1,2]. For children exposed to
carbamazepine and other AEDs such as lamotrigine,
levetiracetam and topiramate, evidence regarding any
effect on specific cognitive skills in older children is
lacking [1,2]. Valproate and carbamazepine exposure
in monotherapy have been associated with language
impairment in several studies [4–9,11,22] but other
Table 3 Language impairment for specific AED therapies in monotherapy, AED polytherapy and any AED exposure
n (%) Crude OR (95% CI) Adjusted OR (95% CI)
Language impairment age 5 yearsa
Children of mothers without epilepsy 9011 of 41 194 (22) NA NA
Valproate 5 of 14 (36) 2.0 (0.7–5.9) 2.2 (0.7–7.0)
Carbamazepine 6 of 17 (35) 1.9 (0.7–5.3) 1.9 (0.6–5.6)
Lamotrigine 9 of 39 (23) 1.1 (0.5–2.3) 1.0 (0.5–2.3)
Levetiracetam 2 of 9 (22) 1.0 (0.2–4.9) 1.0 (0.2–5.3)
Topiramate 2 of 4 (50) 3.6 (0.5–25.4) 5.8 (0.5–64.0)
AED monotherapy 28 of 91 (31) 1.6 (1.0–2.5)* 1.7 (1.0–2.7)*
AED polytherapy 7 of 26 (27) 1.3 (0.6–3.1) 1.4 (0.6–3.4)
Any AED 35 of 117 (30) 1.5 (1.0–2.3)* 1.6 (1.1–2.5)*
Language impairment age 8 yearsb
Children of mothers without epilepsy 8250 of 42 550 (19) NA NA
Valproate 5 of 16 (31) 1.9 (0.7–5.4) 2.2 (0.7–6.4)
Carbamazepine 10 of 23 (43) 3.2 (1.4–7.3)** 3.8 (1.6–9.0)**
Lamotrigine 9 of 41 (22) 1.2 (0.6–2.4) 1.2 (0.6–2.6)
Levetiracetam 1 of 6 (17) 0.8 (0.1–7.1) 0.7 (0.1–6.0)
Topiramate 1 of 4 (25) 1.4 (0.1–13.3) 1.1 (0.1–10.9)
AED monotherapy 30 of 97 (31) 1.9 (1.2–2.9)** 2.0 (1.3–3.0)**
AED polytherapy 7 of 21 (33) 2.1 (0.8–5.2) 2.4 (0.9–6.1)
Any AED 38 of 120 (32) 1.9 (1.3–2.8)*** 2.0 (1.4–3.0)***
AED, antiepileptic drug; CI, confidence interval; OR, odds ratio. AED-exposed children were compared to children of mothers without epi-
lepsy. Significant results are marked with bold values. aLanguage impairment at age 5 years according to the Ages and Stages Questionnaires,
the Speech and Language Assessment Scale or the Twenty Statements about Language-related Difficulties. bLanguage impairment at age
8 years according to the semantic subscale of the Twenty Statements about Language-related Difficulties. Covariates in the model: maternal
age, parental socioeconomic status (single mother, low maternal education (≤9 years), low household income [<400 000 NOK (equals approxi-
mately 41 000 EUR)/year]), parity (pregnancies >21 gestation weeks), maternal prepregnancy body mass index, maternal report of familial lan-
guage delay [sibling, parent, grandparent, aunt, uncle or cousin who was a late talker or had difficulties with either reading or writing or
pronunciation (only in 5 years model)], smoking during pregnancy, alcohol use during pregnancy (consumption ≥1 time per month) (only
8 years model), maternal anxiety/depression symptoms (mean score >1.75 on the Hopkins symptom check list in gestational week 17–19) dur-
ing pregnancy, Apgar score 5 min after birth, gestational age (calculated from the ultrasonographic measurements performed at 18–19 weeks
of gestation; when ultrasound data were unavailable, gestational age was estimated on the basis of the first day of the last menstrual period),
maternal report of seldom/never helping their child read letters and sounds during a typical week at age 5 years (5 years model) or maternal
report of never reading to their child at age 8 years (8 years model). *P value < 0.05. **P value < 0.01 ***P value < 0.001
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Table 4 Mean language scores in children of mothers with and without epilepsy
ASQ scorea
5 years
Mean (SD, 95% CI)
Language 20 scoreb
5 years
Mean (SD, 95% CI)
SLAS scorec
5 years
Mean (SD, 95% CI)
Language
20 scoreb8 years
Mean (SD, 95% CI)
Children of mothers without epilepsy 66.0 (6.7, 65.9–66.1) 25.3 (8.3, 25.3–25.4) 3.5 (0.6, 3.5–3.6) 10.6 (3.8, 10.6–10.6)
AED-unexposed children 66.2 (5.2, 65.4–67.1) 26.1 (8.3, 24.8–27.5) 3.5 (0.5, 3.4–3.6) 11.3 (4.1, 10.6–11.9)*
AED-exposed children 65.7 (7.9, 64.3–67.2) 27.1 (9.0, 25.4–28.7)** 3.4 (0.6, 3.3–3.5)* 12.1 (5.2, 11.2–13.0)**
Valproate monotherapy 64.3 (6.2, 60.7–67.8) 29.4 (12.8, 22.1–36.8) 3.1 (0.6, 2.8–3.5)* 13.0 (6.4, 9.6–16.4)*
Carbamazepine monotherapy 65.3 (7.9, 61.2–69.3) 28.6 (8.1, 24.4–32.8)* 3.3 (0.5, 3.1–3.6) 12.9 (5.3, 10.7–15.2)**
Lamotrigine monotherapy 65.3 (11.4, 61.6–69.1) 24.7 (6.1, 22.7–26.7) 3.4 (0.7, 3.2–3.7) 10.9 (3.7, 9.7–12.1)
Levetiracetam monotherapy 68.0 (2.3, 66.2–69.7) 24.1 (7.0, 18.7–29.5) 3.7 (0.8, 3.1–4.4) 10.0 (2.5, 7.4–12.7)
Topiramate monotherapy 64.6 (6.7, 53.9–75.2) 27.8 (11.2, 10.1–45.6) 3.5 (0.4, 2.9–4.1) 11.0 (3.5, 5.5–16.5)
AED monotherapy 65.6 (8.8, 63.8–67.5) 27.0 (9.4, 25.0–29.0) 3.4 (0.6, 3.3–3.6) 11.9 (4.8, 11.0–12.9)**
AED polytherapy 66.1 (3.5, 64.7–67.5) 27.4 (7.8, 24.2–30.6)* 3.4 (0.5, 3.2–3.6) 13.0 (6.8, 9.9–16.1)
AED, antiepileptic drug; ASQ, Ages and Stages Questionnaires; CI, confidence interval; Language 20, Twenty Statements about Language-re-
lated Difficulties; SLAS, Speech and Language Assessment Scale. AED-exposed and AED-unexposed children were compared to children of
mothers without epilepsy by using the Mann–Whitney U test due to violation of the assumption of normal distribution. Significant results are
marked with bold values. aAges and Stages Questionnaires score (0–70 points). A low score indicates language impairment. bTwenty State-
ments about Language-related Difficulties score (0–100 points total score, 0–40 points semantic subscale). A high score indicates language
impairment. cComposite scale mean score (1–5 points) from the Speech and Language Assessment Scale. A score below 3 points indicates lan-
guage impairment. *P value < 0.05. **P value < 0.01.
Figure 2 The correlation between lan-
guage score and maternal plasma val-
proate concentration (µmol/l) during
pregnancy at age 5 years.
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studies reported no such association for carba-
mazepine [8,9]. Two studies based on neuropsycholog-
ical assessment reported reduced verbal abilities in
children aged 3 and 6 years after foetal carbamazepine
exposure [6,22]. Our results are based on validated
screening instruments. Different study designs and dif-
ferent maternal folate status [23] could explain diver-
gent results between studies. The lack of significantly
increased aORs for language impairment after val-
proate exposure in monotherapy at age 5 and 8 years
is probably due to small numbers of children and low
concentrations of valproate [16]. Nevertheless, a corre-
lation was found between maternal valproate concen-
trations during pregnancy and language impairment.
This is consistent with our previous study of children
aged 18 months in the MoBa [12] and with previous
reports on dose-dependent valproate-mediated lan-
guage impairment [4,5,8].
In this study, the previously reported AED-associ-
ated poorer language abilities in preschool years [11]
have been shown to persist into school age in AED-
exposed children of mothers with epilepsy. Our data
shows that the language impairment at age 5 and
8 years may develop early or emerge later in the pre-
school years in children of mothers with epilepsy, as
in children from the general population [24]. Our find-
ings suggest a possible long-term AED-associated
effect on language abilities in offspring after foetal
AED exposure. Reduced total brain volume and grey
matter volume compared to healthy children have
been reported in valproate-exposed children aged
10 years with low IQ and language dysfunction [25].
Similarly, adults aged 23 years with antenatal expo-
sure to mainly valproate, carbamazepine, phenytoin
or primidone in monotherapy or polytherapy had
reduced grey matter volume compared to healthy con-
trols, and particularly in the left hemisphere control-
ling language [26]. These findings support the notion
of permanently affected language abilities associated
with foetal AED exposure. The protective effect of
periconceptional folic acid supplementation on AED-
associated language impairment was highly evident in
our study. This protection, previously reported for
age 1.5 and 3 years [12] remained equally evident at
age 5 and 8 years. This strongly suggests a role of
folate in the mechanism of AED-associated language
impairment. Furthermore, these findings emphasize
the importance of folic acid supplement use in the
periconceptional period in all women with epilepsy
who use AEDs [5,10,12,22]. Language impairment in
children requires intervention, as it may have severe
consequences for language skills in adulthood, aca-
demic achievements, mental health, behaviour and
social life [21,27].
The strengths of our study include a validated, large
dataset comprising epilepsy groups with and without
AED exposure and a control group without epilepsy.
Plasma AED and folate concentrations were analysed
in the mothers during the pregnancy, as well as umbil-
ical cord AED concentrations. Relevant covariates
were adjusted for. Selection bias in the MoBa has
been reported as moderate and with no or minimal
effects on exposure–outcome association measure-
ments [28]. The response rates for the two epilepsy
groups and the control group were similar, and thus
the exposure–outcome association measurements are
unlikely to be biased.
Our missing data analyses indicated that children
with normal language may be overrepresented. Chil-
dren where mothers reported language impairment at
age 1.5 and 3 years, no exposure to folic acid supple-
mentation and with a lower socioeconomic status were
more often missing from the study at age 5 and 8 years.
Our findings may have been even more pronounced
without any such selection bias. Mothers who used
AEDs during pregnancy may be aware of the potential
neurodevelopmental effects of AED exposure and
might therefore have reported their children’s language
skills more vigilantly. If true, this would make the true
results less pronounced. However, the association
between foetal AED exposure, poor language abilities
and maternal folate status was not well known during
the inclusion period of the MoBa and is therefore unli-
kely to have influenced our results. There was no for-
mal neuropsychological assessment of the children, but
parents are considered good evaluators of the language
abilities of their children [29]. Mothers who use AEDs
during pregnancy are likely to have more severe epi-
lepsy with a higher risk of epileptic seizures than
untreated mothers with epilepsy. It cannot be excluded
that such non-AED factors contribute to our observed
language impairment. Information on maternal IQ was
not available and this variable could not be controlled
for, but education was controlled for in the analyses.
In this study, an association between language
impairment and foetal AED exposure in children aged
5 and 8 years of mothers with epilepsy was found.
Children of mothers with untreated epilepsy had no
increased risk of language impairment. Periconcep-
tional folic acid supplement use had a protective effect
on AED-associated language impairment. Clinicians
should be aware of the risk of poor language abilities
in children exposed to AEDs in utero, particularly val-
proate and carbamazepine, with early intervention for
signs of language impairment. The importance of folic
acid supplement use in all AED-using women with
epilepsy with a chance of becoming pregnant is
emphasized.
© 2019 The Authors. European Journal of Neurology published by John Wiley & Sons Ltd on behalf of European Academy of Neurology
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Appendix S1. Supplementaty data.
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